Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2015 08:30 ET | Source: CytoDyn

Eleven HIV Patients Successfully Reach One Year of Full Virologic Suppression in PRO 140 Monotherapy Phase 2b Extension Study

VANCOUVER, Wash., Dec. 1, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
November 24, 2015 06:30 ET | Source: CytoDyn

CytoDyn Hires New Senior Vice President of Manufacturing for PRO 140

VANCOUVER, Wash., Nov. 24, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
November 18, 2015 06:30 ET | Source: CytoDyn

CytoDyn Announces Investment Community Conference Call

VANCOUVER, Wash., Nov. 18, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
October 22, 2015 06:30 ET | Source: CytoDyn

CytoDyn Injects First Patient in Its Current Phase 3 Study

VANCOUVER, Wash., Oct. 22, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
October 20, 2015 06:30 ET | Source: CytoDyn

CytoDyn Files an IND and Full Protocol for Phase 2 Study in GvHD

VANCOUVER, Wash., Oct. 20, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
September 21, 2015 06:30 ET | Source: CytoDyn

HIV Patients Successfully Reach One Year of Virologic Suppression in PRO 140 Monotherapy Study

VANCOUVER, Wash., Sept. 21, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
August 05, 2015 16:01 ET | Source: CytoDyn

Cytodyn Initiates First Clinical Site for Phase 3 Trial of PRO 140

VANCOUVER, Wash., Aug. 5, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
July 29, 2015 06:30 ET | Source: CytoDyn

CytoDyn Completes Qualification of PRO 140 Material for Phase 3

VANCOUVER, Wash., July 29, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
July 15, 2015 06:30 ET | Source: CytoDyn

Evidence of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months

CytoDyn to Request Meeting With FDA to Discuss Registration Pathway for PRO 140 Monotherapy Indication Dr. Paul J. Maddon, an Inventor of PRO 140, Named Senior Science Advisor VANCOUVER, Wash.,...
June 24, 2015 06:30 ET | Source: CytoDyn

CytoDyn to Expand Clinical Applications for PRO 140 Beyond Therapy for HIV

VANCOUVER, Wash., June 24, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus...